Chemical Property of Regadenoson
Chemical Property:
- Appearance/Colour:Off-white solid
- Melting Point:158-160 °C
- Refractive Index:1.896
- PKA:13.07±0.70(Predicted)
- PSA：186.46000
- Density:1.98 g/cm3
- LogP:-1.46260
- Storage Temp.:-20°C Freezer, Under Inert Atmosphere
- Solubility.:DMSO (Slightly), Methanol (Slightly, Sonicated)
- XLogP3:-1.5
- Hydrogen Bond Donor Count:5
- Hydrogen Bond Acceptor Count:10
- Rotatable Bond Count:4
- Exact Mass:390.14001570
- Heavy Atom Count:28
- Complexity:587
- Purity/Quality:
-
99% *data from raw suppliers
Regadenoson *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N
- Isomeric SMILES:CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
- Recent ClinicalTrials:A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients
- Recent EU Clinical Trials:EVALUATION OF PATIENTS WITH TOTAL CORONARY OCCLUSIONS WITH MULTIMODALITY IMAGE
- Recent NIPH Clinical Trials:An open-label, dose escalation, multicenter study to determine the effect on coronary blood flow and safety of NMB46 in subjects undergoing a clinically indicated cardiac catheterization.
-
Description
Lexiscan ?(regadenoson) is an injectable adenosine A2A
receptor agonist for use as a pharmacologic stress agent in
myocardial perfusion imaging (MPI) studies in patients unable
to undergo adequate exercise induced stress. Regadenoson
is the first adenosine A2A receptor agonist shown
to be safe and effective as a pharmacologic stress agent in
MPI studies. It is delivered as a rapid bolus (approximately
10 seconds) with no dose adjustment required for body
weight. The product was developed under a license and collaboration
agreement between CV Therapeutics and Astellas,
and was launched by Astellas in June of 2008.
-
Uses
A selective A2A adenosine receptor agonist in myocardial imaging Regadenoson is a selective, short-acting adenosine A2A receptor agonist (Ki = 1.1 nM for pig striatum A2A receptor). It increases coronary blood flow 3.4- to 3.8-fold with a half-time to reversal of 1.9-2.6 minutes in open-chest anesthetized pigs. Regadenoson is used to induce hyperemia (increased blood flow), particularly in the context of myocardial perfusion imaging. It has also been found to increase the delivery of compounds to the central nervous system through the blood-brain barrier in animals. Regadenoson is a selective and potent A2A adenosine receptor agonist (1). The adenosine A2A receptor is a G-protein-coupled receptor and a key therapeutic target for oncologic, inflammatory, Parkinson''s and cardiovascular diseases (2). In rodent studies, it has been shown that co-administration of Regadenoson with Temozolomide (T017775) can increase Temozolomide concentration in the brain (3).
